drugset / Trial / NCT05372016
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3
Completed
1200 enrolled
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd. · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
Timeline
- Start
- 2020-09-19
- Primary completion
- 2022-06-17
- Completion
- 2022-06-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9vHPV | Vaccine | 0.5 ml | — |
| Comparator | Gardasil 9 | Vaccine | 0.5 ml | — |